C.Scale | $2,000,000 | (Nov 5, 2025)
Downstream | $8,000,000 | (Nov 5, 2025)
Ruli | $6,000,000 | (Nov 5, 2025) Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
Azalea Therapeutics | $82,000,000 | (Nov 5, 2025)
Sunflower Labs | $16,000,000 | (Nov 5, 2025)
Mine Vision Systems | $12,500,000 | (Nov 5, 2025)
Parable | $11,000,000 | (Nov 5, 2025)
Portal26 | $9,000,000 | (Nov 5, 2025)
Daylight Security | $33,000,000 | (Nov 5, 2025)
Planbase (YC S24) | $2,100,000 | (Nov 5, 2025)
The EVERY Company | $55,000,000 | (Nov 5, 2025)